FOUNDER SPOTLIGHT
DAPHNE PREUSS
President and CEO, Chromatin, Inc.
“As a result of funding from the DOE, NIH and Department of Commerce, Chromatin’s technology is being tested by leading multinational companies and Chromatin is partnering with several emerging technology companies to create crops that sustainably meet growing global demands."
FAST FACTS
FOUNDER(S):
Dr. Daphne Preuss
INNOVATION(S):
Argiculture/Life Sciences
Bio Fuels/Bio Chemicals
EMPLOYEES:
30
HEADQUARTERS:
Chicago, IL
FOUNDED:
2001
TSC MEMBER INSTITUTION(S):
University of Chicago
FUNDING AGENCY(S):
National Science Foundation
STATUS:
Private
|
CHROMATIN, INC.
UNLOCKING THE HIDDEN POTENTIAL IN NATURE
ABOUT THE COMPANY:
Chromatin’s patented mini-chromosome technologies enable the development of new seed products and the delivery of multiple genetic traits. Consumers, growers, seed companies, and processors derive greater value from crop plants through the application of Chromatin’s technologies. More efficient and faster product development, greater product differentiation, and creation of novel products are among the benefits Chromatin’s technologies deliver to these users.
Chromatin is now entering the bioenergy feedstock market, where there are significant opportunities to create and capture value using the company’s transformation technology. Chromatin’s first feedstock products are targeting crops such as switchgrass, miscanthus, sorghum and sugarcane where the addition of traits can improve crop and sugar yield and allow digestion of cellulosic fiber. Chromatin is also using this synthetic biology technology to develop scalable and competitive solutions for the North American cellulosic biofuels market.
UNIVERSITY-BASED RESEARCH CONNECTION:
Dr. Daphne Preuss did pioneering research into chromosomes and chromosome assembly at the University of Chicago. Working with Arabidopsis, a weed variant of mustard, she invented techniques for identifying the location of centromeres and for inserting gene plasmids. In 2000, the team secured its first of many patents through the University of Chicago; in 2004 the company received $7.3 million in funding.
ROLE OF FEDERAL RESEARCH FUNDING:
The majority of Dr. Preuss’ enabling work was funded by National Science Foundation grants.
 Read The Full Report Here
|
Printer-Friendly Version
CHROMATIN, INC.